William Blair Predicts Ikena Oncology FY2029 Earnings

Ikena Oncology, Inc. (NASDAQ:IMA) – Stock analysts at William Blair issued their FY2029 earnings per share estimates for Ikena Oncology in a research note issued to investors on Wednesday, July 30th. William Blair analyst M. Phipps expects that the company will earn ($5.41) per share for the year. The consensus estimate for Ikena Oncology’s current full-year earnings is ($0.91) per share.

Separately, Wedbush reduced their price target on Ikena Oncology from $25.00 to $23.00 and set a “neutral” rating for the company in a report on Friday, July 25th.

Ikena Oncology Trading Down 3.5%

NASDAQ IMA opened at $17.28 on Friday. The stock has a market capitalization of $69.47 million, a price-to-earnings ratio of -2.25 and a beta of 0.51. Ikena Oncology has a twelve month low of $11.65 and a twelve month high of $23.28. The stock has a 50-day moving average of $15.97 and a 200 day moving average of $15.79.

Ikena Oncology (NASDAQ:IMA) last issued its earnings results on Thursday, July 24th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.08.

Insider Transactions at Ikena Oncology

In other Ikena Oncology news, Director Otello Stampacchia purchased 267,556 shares of Ikena Oncology stock in a transaction that occurred on Friday, July 25th. The stock was bought at an average price of $29.90 per share, with a total value of $7,999,924.40. Following the acquisition, the director owned 454,982 shares of the company’s stock, valued at $13,603,961.80. This trade represents a 142.75% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director David P. Bonita purchased 83,611 shares of Ikena Oncology stock in a transaction that occurred on Friday, July 25th. The stock was acquired at an average cost of $29.90 per share, with a total value of $2,499,968.90. Following the acquisition, the director directly owned 287,885 shares in the company, valued at $8,607,761.50. This trade represents a 40.93% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 5.94% of the company’s stock.

Hedge Funds Weigh In On Ikena Oncology

A number of hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its holdings in shares of Ikena Oncology by 62.4% during the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock valued at $98,000 after acquiring an additional 29,369 shares during the last quarter. Aldebaran Capital LLC acquired a new position in shares of Ikena Oncology during the first quarter valued at approximately $317,000. XTX Topco Ltd raised its holdings in shares of Ikena Oncology by 350.6% during the first quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock valued at $72,000 after acquiring an additional 43,924 shares during the last quarter. BML Capital Management LLC raised its holdings in shares of Ikena Oncology by 3.5% during the first quarter. BML Capital Management LLC now owns 3,710,803 shares of the company’s stock valued at $4,750,000 after acquiring an additional 124,937 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Ikena Oncology during the fourth quarter valued at approximately $72,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

About Ikena Oncology

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.